Biotech Values

[cjgaddy]

PCrutch, still hittin’ the PPHM, huh? Enjoy your SMILING while it lasts.

Just posted this to your latest SA hatchet job copy/paste…

Hey Patrick Crutcher (PCrutch/PSlice84/MEGarza, whatever), I see this is a Copy/Paste of your Aug.24 2012 “Chimera Research Group” hatchet job on Peregrine.
• I see you left out your NAME this time.
• Changed the Title a touch – that’s commendable.
• Went with Aug.27 this time rather than the orig. Aug.24.
• Very Clever, PCrutch!
• Says it all: “Disclosure: I AM SHORT PPHM.”
• Good luck with your Smiling after Gerber plenaries on Sept. 7th.

= = = = = =
THIS ONE: 8-27-12: “More Downside Expected In Peregrine Pharmaceuticals”
By: ((anonymous))
“There appears to be significant reason to be cautious with this name. . .” etc etc etc
http://seekingalpha.com/article/828911-more-downside-expected-in-peregrine-pharmaceuticals

COPY OF: 8-24-12 “PPHM – More downside expected in Peregrine Pharmaceuticals”
AUGUST 24, 2012, Chimera Research Group
“There appears to be significant reason to be cautious with this name. . .” etc etc etc
http://www.chimeraresearchgroup.com/2012/08/quick-analysis-on-peregrine-pharmaceuticals

= = = = = = = = = = = = = = =
To anyone gullible enough to put any stock in PCrutch’s repeated, coordinated hatchet jobs…

These two posts by you on BV’s clearly bare PCrutch’s true feelings & motives for all to see:

By PCRUTCH iHub-BVAL #146814 8-9-12
“Well I am EXPECTING TRIPLE FAILURE of all their trials this fall (NSCLC 1st & 2nd line, Pancreatic). I WILL BE SMILING THEN.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78376986

By PCRUTCH iHub-BVAL #146826 8-9-12 5:53PM (post removed)
“…I THINK IT'S CRIMINAL PPHM IS STILL GIVING THEIR DRUG TO PATIENTS.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78383525 (post removed for some reason)

= = = = = = = = = = = = = = =
As opposed to:

1-11-11: “Peregrine Seems Poised For Growth In 2011”
by Patrick Crutcher
http://biomedreports.com/2011011162299/peregrine-poised-for-growth-in-2011.html
Back then you said you were LONG on PPHM, and you wrote,
“Bavituximab is an extremely interesting molecule which has created a lot of buzz over the past 2 years; not just in oncology but also as a potent anti-viral. . . PPHM entered into an ATM with MLV to the tune of $75 million. we view this deal positively, since it allows them to raise capital as share price increases and it is not selling them at a discount to a fund. They have one of the best un-partnered pipelines amongst small-cap biotechs and we are excited about the potential over at Peregrine.”